Skip to content
Invitrocue - Transforming bioanalytics
  • Home
  • About Us
    • Meet Invitrocue
    • Our Team
    • Partners
    • Corporate Governance
    • Careers
  • Oncology
    • Onco-PDO™
    • Patient FAQ
    • Physician FAQ
  • Preclinical Services
    • Overview
    • Drug Metabolism and Pharmacokinetics
    • Toxicology and Safety Assessment
    • Hepatocytes
    • 3D Cell Culture
    • Patient-derived Organoid (PDO)
    • Immunomodulatory Assays
    • Customized Assays and Disease Modelling
    • Invivocue – Humanized Mice
  • Shareholders
    • Reports
      • Financial Reports
      • Analyst Reports
    • Announcements
    • Contact Management
  • News & Resources
    • Publications
    • Conferences & Events
    • Press Releases
    • Privacy Policy
  • Contact Us
  • English
    • English
    • Deutsch
    • Español
    • Português
    • 中文 (中国)
    • 中文 (香港)
  • Home
  • About Us
    • Meet Invitrocue
    • Our Team
    • Partners
    • Corporate Governance
    • Careers
  • Oncology
    • Onco-PDO™
    • Patient FAQ
    • Physician FAQ
  • Preclinical Services
    • Overview
    • Drug Metabolism and Pharmacokinetics
    • Toxicology and Safety Assessment
    • Hepatocytes
    • 3D Cell Culture
    • Patient-derived Organoid (PDO)
    • Immunomodulatory Assays
    • Customized Assays and Disease Modelling
    • Invivocue – Humanized Mice
  • Shareholders
    • Reports
      • Financial Reports
      • Analyst Reports
    • Announcements
    • Contact Management
  • News & Resources
    • Publications
    • Conferences & Events
    • Press Releases
    • Privacy Policy
  • Contact Us
  • English
    • English
    • Deutsch
    • Español
    • Português
    • 中文 (中国)
    • 中文 (香港)

ASX Announcements

Proposed issue of securities

June 26, 2018

Proposed issue of securities

Categories ASX Announcements

Change in substantial holding

May 25, 2018

Change in substantial holding

Categories ASX Announcements

Appendix 4C – quarterly

April 30, 2018

Appendix 4C – quarterly

Categories ASX Announcements, Financial Reports

Appendix 4G

April 27, 2018

Appendix 4G

Categories ASX Announcements

IVQ launches Personalised Cancer Screening Service Onco-PDO

April 13, 2018

Invitrocue launches world’s first commercial Personalised Cancer Screening Service: Onco-PDO™

Categories ASX Announcements, News, Press Releases

Half Yearly Report and Accounts

February 28, 2018

Half Yearly Report and Accounts

Categories ASX Announcements, Financial Reports, News

Grant from Northern Ireland to commercialize Onco-PDO

February 26, 2018

Invitrocue secures grant from Northern Ireland to commercialise Onco-PDO

Categories ASX Announcements, News, Press Releases

Investor Presentation

February 23, 2018

Investor presentation

Categories ASX Announcements, News

Change of Director's Interest Notice – Jamie Khoo

February 20, 2018

Change of Director’s Interest Notice – Jamie Khoo

Categories ASX Announcements, News

Change of Director's Interest Notice – Steven Fang

February 20, 2018

Change of Director’s Interest Notice – Steven Fang

Categories ASX Announcements, News
Post navigation
Older posts
Newer posts
← Previous Page1 … Page7 Page8 Page9 … Page16 Next →

Recent Posts

  • Strategic partnership & Financial advisor appointment
  • Invitrocue announces acquisition of Welala to create life science leadership in Thailand and Asean
  • Invitrocue’s Onco-PDO test is Singapore’s and world’s first validated and approved Clinical Cancer Drug Screening service for Personalised Oncology
  • Operational Updates – February 2024
  • Operational Updates – October 2023

GET IN TOUCH

51 Science Park Road, #01-11/13 The Aries, Singapore Science Park II Singapore 117586

GENERAL / PHARMACOLOGY ENQUIRIES:

+65 6460 0497
contact@invitrocue.com

ONCO-PDO ENQUIRIES:

+65 6819 0181
onco-pdo@invitrocue.com
SAC - SINGLAS Accredited Laboratory

SERVICES

Home
About Us
Oncology
Preclinical Services
Investors
News & Resources
Contact Us

Logo Invitrocue
Icon-twitter-x Facebook-f Linkedin-in Youtube

© Copyright 2026 Invitrocue. All rights reserved
Impressum | Privacy Policy | Cookies Policy | Cookie Settings